Science News
from research organizations

Hypofractionated Stereotactic Radiotherapy Beneficial For Recurrent Low-grade Glioma, Study Suggests

Date:
April 21, 2009
Source:
Thomas Jefferson University
Summary:
Hypofractionated stereotactic radiotherapy was well-tolerated and improved symptoms in patients with recurrent low-grade glioma, according to new research.
Share:
         
Total shares:  
FULL STORY

Hypofractionated stereotactic radiotherapy was well-tolerated and improved symptoms in patients with recurrent low-grade glioma, according to researchers from the Kimmel Cancer Center at Jefferson. The data were presented at the AACR 100th Annual Meeting 2009.

In a subgroup of patients who also received chemotherapy with their hypofractionated sterotactic radiotherapy (H-SRT) the median survival time was more than three times longer than patients who only received H-SRT alone according to Shannon Fogh, M.D., a resident in Radiation Oncology at Thomas Jefferson University Hospital.

The study included 22 patients with evidence of glioma recurrence. All patients were given H-SRT as salvage therapy, and nine of the patients also received chemotherapy. The most common regimen was temozolomide (Temodar).

The median survival time from the time of H-SRT was nine months. Eleven of the patients had a response to treatment at six-week follow-up. In the subset of patients who received chemotherapy, the median survival time from time of H-SRT was 17 months vs. four months for patients who only received H-SRT.

The role of chemotherapy needs to be evaluated further, Dr. Fogh said, since the small number of patients in this study prevented a multivariate analysis that would account for age, performance status and tumor size.

"There really is no standard of care for recurrent gliomas," Dr. Fogh said. "H-SRT would be an attractive option because it allows a patient to have a shorter course of treatment. In our study, H-SRT was well-tolerated, and all patients were able to complete the full course of treatment."


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Hypofractionated Stereotactic Radiotherapy Beneficial For Recurrent Low-grade Glioma, Study Suggests." ScienceDaily. ScienceDaily, 21 April 2009. <www.sciencedaily.com/releases/2009/04/090421101623.htm>.
Thomas Jefferson University. (2009, April 21). Hypofractionated Stereotactic Radiotherapy Beneficial For Recurrent Low-grade Glioma, Study Suggests. ScienceDaily. Retrieved April 27, 2015 from www.sciencedaily.com/releases/2009/04/090421101623.htm
Thomas Jefferson University. "Hypofractionated Stereotactic Radiotherapy Beneficial For Recurrent Low-grade Glioma, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/04/090421101623.htm (accessed April 27, 2015).

Share This Page:


Health & Medicine News
April 27, 2015

Latest Headlines
updated 12:56 pm ET